- 5,039
- 7,458
- Joined
- Jun 20, 2014
#ModernaGang winning? (Self) Reported 93% efficacy after 6 months in most recent press release
Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose
Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2
Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231)
Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates | Moderna, Inc.
Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2 Dosing started in Phase 1
investors.modernatx.com
Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose
Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2
Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231)
Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders